

## Cytokinetics to Present at March Investor Conferences

2016-03-01

SOUTH SAN FRANCISCO, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the following investor conferences:

- **Cowen and Company 36<sup>th</sup> Annual Health Care Conference** on Monday, March 7, 2016 at 2:00 PM EST at the Boston Marriott Copley Place in Boston, MA
- **28<sup>th</sup> Annual ROTH Conference** on Monday, March 14, 2016 at 11:30 AM PST at the Ritz-Carlton, Laguna Niguel in Dana Point, CA

Interested parties may access the live webcast of these presentations by visiting the Investors & Media section of the Cytokinetics website at [www.cytokinetics.com](http://www.cytokinetics.com). The webcast replays of the presentations will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of each event.

### About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is *tirasemtiv*, a fast skeletal muscle activator, for the potential treatment of ALS. *Tirasemtiv* has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics retains the right to develop and commercialize *tirasemtiv*. Cytokinetics is collaborating with Amgen Inc. to develop *omecamtiv mecarbil*, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Amgen holds an exclusive license worldwide to develop and commercialize *omecamtiv mecarbil* and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights. For

additional information about Cytokinetics, visit [www.cytokinetics.com](http://www.cytokinetics.com).

Contact:  
Cytokinetics  
Diane Weiser  
Vice President, Corporate Communications, Investor Relations  
(650) 624-3060

Cytokinetics, Inc